Serine/threonine-specific protein kinase

Specific Proteins Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update

Retrieved on: 
Friday, November 25, 2022
Protein, Medical device, Clinical formulation, D, Serine/threonine-specific protein kinase, Segment

Specific Proteins Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 UpdateRead the full report: https://www.reportlinker.com/p06365185/?utm_source=PRN SummaryMedical Devices sector report, “Specific Proteins Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update" provides comprehensive information about the Specific Proteins pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.Specific Proteins are reagents and test kits which are used to quantify and detect protein molecules from bodily fluids.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.Scope- Extensive coverage of the Specific Proteins under development- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities- The report reviews the major players involved in the development of Specific Proteins and list all their pipeline projects- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage- The report provides key clinical trial data of ongoing trials specific to pipeline products- Recent developments in the segment / industryReasons to BuyThe report enables you to -- Formulate significant competitor information, analysis, and insights to improve R&D strategies- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage- Identify and understand important and diverse types of Specific Proteins under development- Develop market-entry and market expansion strategies- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline- In-depth analysis of the product’s current stage of development, territory and estimated launch dateRead the full report: https://www.reportlinker.com/p06365185/?utm_source=PRN About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001

Key Points: 
  • Specific Proteins Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update
    Medical Devices sector report, Specific Proteins Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update" provides comprehensive information about the Specific Proteins pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
  • Specific Proteins are reagents and test kits which are used to quantify and detect protein molecules from bodily fluids.
  • Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Treadwell Announces Initiation of Patient Dosing in TWT-202, a Phase 1b/2 study of PLK4 Inhibitor, CFI-400945, in Patients with Leukemia

Retrieved on: 
Thursday, April 29, 2021
Biotechnology, Health, Oncology, Clinical trials, Enzymes, PLK4, Protein kinases, Serine/threonine-specific protein kinase

\xe2\x80\x9cPrevious clinical studies have shown that CFI-400945 can lead to single agent complete remissions in high-risk refractory AML patients.

Key Points: 
  • \xe2\x80\x9cPrevious clinical studies have shown that CFI-400945 can lead to single agent complete remissions in high-risk refractory AML patients.
  • The trial will enrol approximately 72 patients at up to 20 sites in North America and Asia.
  • PLK4 is overexpressed in a variety of solid tumors and elevated expression is associated with poor clinical outcomes.
  • CFI-400945 is a potent, selective, orally administered, first-in-class inhibitor of the serine/threonine kinase, polo-like kinase 4 (PLK4).

High Cancer Prevalence and Rise in Number of Pharmacies to Boost Growth Rate of Kinase Inhibitors Market: TMR

Retrieved on: 
Tuesday, January 26, 2021
Enzymes, Protein kinases, Tyrosine kinase inhibitor, Tyrosine kinase, Protein kinase, Kinase, Serine/threonine-specific protein kinase, mTOR inhibitors, MAP kinase kinase kinase

The growing utilization of kinase inhibitors in cancer therapies may bring immense growth prospects for the kinase inhibitors market.

Key Points: 
  • The growing utilization of kinase inhibitors in cancer therapies may bring immense growth prospects for the kinase inhibitors market.
  • Various drug discovery programs have led to effective kinase inhibitors, thus influencing the growth of the kinase inhibitors market to a great extent.
  • The utilization of tyrosine kinase inhibitors for treating a plethora of autoimmune and inflammatory skin diseases may bring expansive growth prospects for the kinase inhibitors market.
  • Gain insights into theKinase Inhibitors Market (Type: Non-receptor Tyrosine Kinase Inhibitors, Receptor Tyrosine Kinase Inhibitors, Multikinase Inhibitors, Serine/Threonine Kinase Inhibitors, Protein Kinase C Inhibitors, RHO Kinase Inhibitors, and Others; Application: Oncology, Inflammatory Diseases, and Others; and Distribution Channel: Hospital Pharmacies, Independent Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027 at https://www.transparencymarketresearch.com/report-toc/818
    North America's kinase inhibitors market is extrapolated to invite tremendous growth opportunities across the assessment period.

High Cancer Prevalence and Rise in Number of Pharmacies to Boost Growth Rate of Kinase Inhibitors Market: TMR

Retrieved on: 
Tuesday, January 26, 2021
Enzymes, Protein kinases, Tyrosine kinase inhibitor, Tyrosine kinase, Protein kinase, Kinase, Serine/threonine-specific protein kinase, mTOR inhibitors, MAP kinase kinase kinase

The growing utilization of kinase inhibitors in cancer therapies may bring immense growth prospects for the kinase inhibitors market.

Key Points: 
  • The growing utilization of kinase inhibitors in cancer therapies may bring immense growth prospects for the kinase inhibitors market.
  • Various drug discovery programs have led to effective kinase inhibitors, thus influencing the growth of the kinase inhibitors market to a great extent.
  • The utilization of tyrosine kinase inhibitors for treating a plethora of autoimmune and inflammatory skin diseases may bring expansive growth prospects for the kinase inhibitors market.
  • Gain insights into theKinase Inhibitors Market (Type: Non-receptor Tyrosine Kinase Inhibitors, Receptor Tyrosine Kinase Inhibitors, Multikinase Inhibitors, Serine/Threonine Kinase Inhibitors, Protein Kinase C Inhibitors, RHO Kinase Inhibitors, and Others; Application: Oncology, Inflammatory Diseases, and Others; and Distribution Channel: Hospital Pharmacies, Independent Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027 at https://www.transparencymarketresearch.com/report-toc/818
    North America's kinase inhibitors market is extrapolated to invite tremendous growth opportunities across the assessment period.

Protein Kinase C Theta Type, Pipeline Review, H1 2020: Stage of Development, Mechanism of Action, Route of Administration & Molecule Type - ResearchAndMarkets.com

Retrieved on: 
Friday, January 31, 2020
Health, Pharmaceutical, Enzymes, Protein kinases, PRKCQ, Protein kinase C, Protein kinase, Serine/threonine-specific protein kinase, Kinase

The "Protein Kinase C Theta Type - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Protein Kinase C Theta Type - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Protein kinase C theta (PKC-) is an enzyme encoded by the PRKCQ gene.
  • Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) pipeline Target constitutes close to 9 molecules.
  • The latest report Protein Kinase C Theta Type - Pipeline Review, H1 2020, outlays comprehensive information on the Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Pipeline Review of RAC Beta Serine/Threonine Protein Kinase - H1, 2020 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 30, 2020
Biotechnology, Pharmaceutical, Health, Enzymes, Protein kinases, AKT2, Serine/threonine-specific protein kinase, Protein kinase B, Protein kinase, Kinase, AKT1, Cdc42 binding protein kinase beta

RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) pipeline Target constitutes close to 9 molecules.

Key Points: 
  • RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) pipeline Target constitutes close to 9 molecules.
  • The latest report RAC Beta SerineThreonine Protein Kinase - Pipeline Review, H1 2020, outlays comprehensive information on the RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - RAC-beta serine/threonine-protein kinase is an enzyme encoded by the AKT2 gene.
  • Furthermore, this report also reviews key players involved in RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

Cyclin Dependent Kinase 6 - Pipeline Review, H2 2019 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 20, 2020
Biotechnology, Pharmaceutical, Health, Enzymes, Branches of biology, Cell Cycle, Proteins, Cyclin-dependent kinase 6, Protein kinase, Cyclin, Serine/threonine-specific protein kinase, Kinase, Cyclin-dependent kinase 4, CDKN2C

The "Cyclin Dependent Kinase 6 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cyclin Dependent Kinase 6 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Cell division protein kinase 6 (CDK6) is an enzyme encoded by the CDK6 gene.
  • Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) pipeline Target constitutes close to 30 molecules.
  • The latest report Cyclin Dependent Kinase 6 - Pipeline Review, H2 2019, outlays comprehensive information on the Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

RAC Alpha Serine Threonine Protein Kinase - Pipeline Review, H2 2019 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 17, 2020
Health, Pharmaceutical, Enzymes, Protein kinases, AKT1, Oncogenes, Serine/threonine-specific protein kinase, Protein kinase B, Book:Bc3sigtrann, AKT2

The "RAC Alpha Serine Threonine Protein Kinase - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "RAC Alpha Serine Threonine Protein Kinase - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to the recently published report 'RAC Alpha SerineThreonine Protein Kinase - Pipeline Review, H2 2019'; RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) pipeline Target constitutes close to 13 molecules.
  • RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - RAC-alpha serine/threonine-protein kinase is an enzyme encoded by the AKT1 gene.
  • The report 'RAC Alpha SerineThreonine Protein Kinase - Pipeline Review, H2 2019' outlays comprehensive information on the RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

Serine Threonine Protein Kinase Pim 2, Pipeline Review, H2 2019: Amgen Inc, Inflection Biosciences Ltd & Zovis Pharmaceuticals - ResearchAndMarkets.com

Retrieved on: 
Friday, January 17, 2020
Health, Pharmaceutical, Enzymes, Protein kinases, PIM2, Serine/threonine-specific protein kinase, Protein kinase, MOS, Casein kinases

The "Serine Threonine Protein Kinase Pim 2 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Serine Threonine Protein Kinase Pim 2 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to the recently published report 'SerineThreonine Protein Kinase Pim 2 - Pipeline Review, H2 2019'; Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) pipeline Target constitutes close to 10 molecules.
  • Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Serine/threonine-protein kinase Pim-2 is an enzyme encoded by the PIM2.
  • The report 'SerineThreonine Protein Kinase Pim 2 - Pipeline Review, H2 2019' outlays comprehensive information on the Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

RAC Gamma Serine Threonine Protein Kinase - Pipeline Review, H2 2019 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 17, 2020
Health, Pharmaceutical, Enzymes, Protein kinases, AKT3, Serine/threonine-specific protein kinase, Protein kinase B, Kinase, Protein kinase A, AKT1, AKT2

The "RAC Gamma Serine Threonine Protein Kinase - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "RAC Gamma Serine Threonine Protein Kinase - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) pipeline Target constitutes close to 9 molecules.
  • The latest report RAC Gamma SerineThreonine Protein Kinase - Pipeline Review, H2 2019, outlays comprehensive information on the RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) - RAC-gamma serine/threonine-protein kinase is an enzyme encoded by the AKT3 gene.